INCY: CALR (989) delivers strong MF benefits as the portfolio shifts toward high-growth assets
Less than 1 min read
Transitioning to a diversified Heme-Onc and I&I portfolio, the company is advancing seven priority R&D projects, with key assets like CALR (989) showing strong clinical benefits in MF. Jakafi XR and Niktimvo are positioned for significant commercial impact as the business prepares for post-2029 growth.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr